GGrantIndex
← Leaderboards

Victor M. Karpyak

Mayo Clinic Rochester

$3,624,336
Attributed
$7,248,671
Total exposure
6
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.5M · FY201625
$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$7,248,671 · 6

By mechanism

U01$4,386,503 · 2
R01$2,027,416 · 2
R21$834,752 · 2

Top collaborators

Most similar at Mayo Clinic Rochester

Same institution · by research overlap

Others in their field

Top investigators on “Alcohol Use Disorder

Research focus

Alcohol Use DisorderTreatment ResponseSamplingGenesGenome-WideSelection For TreatmentsTreatment OutcomePathway InteractionsResponseGenome Wide Association StudyPharmaceutical PreparationsAcamprosateHeavy DrinkingPharmacogenomicsGeneticGenetic VariationGenetic MarkersPhenotypeGlutamatesBiological MarkersCandidate Disease GenePlacebosProblem DrinkerTreatment Strategy

Grant awards (17)

Neurosteroids and Alcohol Use Disorder$734,283
R01 · FY2025 · AA · contact PI
Genomics of Alcohol Withdrawal and Treatment Response to Benzodiazepines$374,995
R01 · FY2025 · AA · contact PI
Integrated Therapies for Alcohol use in Alcohol-associated Liver Disease (ITAALD) – Mayo Clinic$355,080
U01 · FY2025 · AA
Genomics of Alcohol Withdrawal and Treatment Response to Benzodiazepines$369,593
R01 · FY2024 · AA · contact PI
Integrated Therapies for Alcohol use in Alcohol-associated Liver Disease (ITAALD) – Mayo Clinic$355,080
U01 · FY2024 · AA
Genomics of Alcohol Withdrawal and Treatment Response to Benzodiazepines$548,545
R01 · FY2023 · AA · contact PI
Pharmacogenomics of Acamprosate Treatment Outcome (Supplement)$155,616
U01 · FY2023 · AA · contact PI
PHARMACOGENOMICS OF ACAMPROSATE TREATMENT OUTCOME$416,055
U01 · FY2022 · AA · contact PI
PHARMACOGENOMICS OF ACAMPROSATE TREATMENT OUTCOME$676,116
U01 · FY2021 · AA · contact PI
PHARMACOGENOMICS OF ACAMPROSATE TREATMENT OUTCOME$719,820
U01 · FY2020 · AA · contact PI
IMPACT OF SEX-RELATED HORMONE LEVELS AND GENETIC VARIATION ON ALCOHOL USE DISORDERS AND RELATED PHENOTYPES IN MALES AND FEMALES$228,563
R21 · FY2020 · AA
PHARMACOGENOMICS OF ACAMPROSATE TREATMENT OUTCOME$754,148
U01 · FY2019 · AA · contact PI
PHARMACOGENOMICS OF ACAMPROSATE TREATMENT OUTCOME$190,678
U01 · FY2019 · AA · contact PI
IMPACT OF SEX-RELATED HORMONE LEVELS AND GENETIC VARIATION ON ALCOHOL USE DISORDERS AND RELATED PHENOTYPES IN MALES AND FEMALES$188,813
R21 · FY2019 · AA
PHARMACOGENOMICS OF ACAMPROSATE TREATMENT OUTCOME$763,910
U01 · FY2018 · AA · contact PI
Pharmacogenomics of Treatment Outcomes in Alcohol Use Disorders$149,063
R21 · FY2017 · AA
Pharmacogenomics of Treatment Outcomes in Alcohol Use Disorders$268,313
R21 · FY2016 · AA